Vedolizumab相关论文
乌司奴单克隆抗体（UST）和维得利珠单克隆抗体（VDZ）在中国已经上市1年余，初始对药物治疗应答的患者在后续继续治疗的过程中均可能存在失......
多种生物制剂已被批准用于治疗炎症性肠病（IBD）。但由于缺乏比较生物制剂间疗效和安全性的头对头的随机对照研究，以及缺乏准确预测生......
目的分析可作为中重度溃疡性结肠炎新型治疗药物抗整合素抗体疗效评估和预测的关键基因。方法从美国国立生物技术信息中心的Gene E......
美国FDA于2014年5月20日批准武田(Takeda)制药公司的Vedolizumab(参考译名:维多珠单抗,商品名:Entyvio)粉针剂上市,用于中至重度溃......
BACKGROUND Fistula and intraabdominal abscess are common complications of Crohn’s disease(CD),but complex rectal fistul......
AIM To conduct a meta-analysis examining theeffectiveness and safety of vedolizumab for thetreatment of ulcerative colit......
The review summarises the key data on the efficacy and the safety of vedolizumab in the management of ulcerative colitis......
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases:A 20
Ulcerative colitis and Crohn’s disease are the main entities of inflammatory bowel disease characterized by chronic rem......
The biologic antitumor necrosis factor alpha(anti-TNFα)agents have revolutionised the treatment of inflammatory bowel d......
BACKGROUND Refractory pouchitis is a common cause of pouch failure,which may require surgical excision of the pouch or p......
2013年12月9日,美国食品和药物管理局（FDA）胃肠药物顾问委员会（GIDAC）及药品安全和风险管理咨询委员会（DSaRMAC）召开联合会议,批准Vedoli......
期刊
Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of A
BACKGROUND Vedolizumab(VDZ),a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved......
<正>美国FDA于2014年5月20日批准Entyvio(vedolizumab)注射剂用于治疗成人中重度溃疡性结肠炎和成人中重度克罗恩病(Crohn’s dise......
